Please Wait.....
Report
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034
Market Report I 2025-05-12 I 300 Pages I EMR Inc.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034
The global glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 19.70 billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity across the globe. The market is anticipated to grow at a CAGR of 10.20% during the forecast period of 2025-2034, with the value likely to reach USD 52.03 billion by 2034.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis
The global Glucagon-Like Peptide-1 (GLP-1) agonists market is experiencing significant growth due to the increasing prevalence of type 2 diabetes and obesity. GLP-1 agonists are widely used for glycaemic control and weight management, offering advantages such as improved insulin secretion, delayed gastric emptying, and appetite suppression. These drugs have gained substantial market traction due to their superior efficacy compared to traditional diabetes treatments. The market is being driven by expanding therapeutic applications, technological advancements in drug delivery, and rising healthcare awareness.
Market Drivers
- Rising Prevalence of Type 2 Diabetes and Obesity - Increasing sedentary lifestyles, poor dietary habits, and genetic predispositions have led to a global surge in type 2 diabetes and obesity, fuelling demand for GLP-1 agonists.
- Favourable Clinical Outcomes - GLP-1 agonists demonstrate significant advantages over conventional treatments, including weight loss benefits, lower hypoglycaemia risks, and cardiovascular protection, increasing their adoption.
- Advancements in Drug Formulations and Delivery Methods - Innovations such as once-weekly dosing, oral formulations, and combination therapies have enhanced patient compliance, boosting market growth.
- Government and Private Healthcare Initiatives - Supportive policies, subsidies, and reimbursement programmes for diabetes and obesity management are accelerating market expansion, particularly in developed economies.
Market Challenges
- High Cost of GLP-1 Agonists - Despite their effectiveness, the high cost of these drugs limits access, especially in low- and middle-income countries.
- Adverse Side Effects - Common side effects such as nausea, vomiting, and gastrointestinal discomfort can lead to treatment discontinuation, affecting market penetration.
- Regulatory and Reimbursement Barriers - Stringent approval processes and varying reimbursement policies across regions pose challenges for market growth.
- Competition from Alternative Therapies - The availability of other diabetes and weight management treatments, including SGLT2 inhibitors and insulin therapies, creates competitive pressure.
Future Opportunities
- Expansion of Indications Beyond Diabetes - Ongoing research into GLP-1 agonists for conditions such as cardiovascular diseases and neurodegenerative disorders could expand market potential.
- Growth in Emerging Markets - Increasing healthcare infrastructure and rising awareness in Asia-Pacific and Latin America offer lucrative growth opportunities.
- Development of Next-Generation Therapies - Innovations in dual and triple receptor agonists promise improved efficacy and broader therapeutic applications.
- Strategic Collaborations and Biosimilar Development - Partnerships between pharmaceutical companies and the emergence of biosimilars could enhance affordability and market reach.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends
The global GLP-1 agonists market is witnessing rapid expansion, driven by increasing diabetes prevalence and evolving treatment approaches. Key trends highlight advancements in drug formulations, rising adoption for weight management, and expanding therapeutic applications.
1. Shift Towards Once-Weekly and Oral Formulations
Pharmaceutical companies are focusing on developing extended-release formulations and oral GLP-1 agonists to improve patient compliance. Once-weekly injections and pill-based alternatives, such as semaglutide, are gaining traction, reducing the burden of frequent dosing.
2. Increasing Use for Obesity and Weight Management
GLP-1 agonists are now widely prescribed for obesity management beyond diabetes treatment. The growing recognition of their weight-loss benefits has led to regulatory approvals and increased adoption in non-diabetic populations seeking effective weight control solutions.
3. Cardiovascular and Metabolic Benefits Driving Adoption
Recent studies highlight the cardiovascular benefits of GLP-1 agonists, including reduced heart disease risks. These findings have led to broader clinical acceptance and integration into treatment guidelines for patients with metabolic disorders.
4. Expanding Applications Beyond Diabetes
Research is exploring the potential of GLP-1 agonists in treating conditions such as non-alcoholic fatty liver disease (NAFLD), neurodegenerative disorders, and polycystic ovary syndrome (PCOS). This diversification is expected to create new revenue streams for market players.
5. Increasing Investment in Biosimilars and Generics
As patents for leading GLP-1 agonists approach expiration, pharmaceutical companies are investing in biosimilar and generic alternatives to enhance affordability and market penetration, particularly in developing regions.
6. Strategic Partnerships and Mergers Accelerating Market Growth
Major pharmaceutical companies are engaging in collaborations and acquisitions to expand their GLP-1 product portfolios. Partnerships between biotech firms and established drug manufacturers are fostering innovation in drug development and delivery systems.
7. Digital Health Integration Enhancing Treatment Monitoring
The rise of digital health solutions, including smart insulin pens and AI-driven treatment monitoring, is improving adherence and treatment outcomes for GLP-1 agonist users, further driving market expansion.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation
Market Breakup by Drugs
- Dulaglutide
- Exenatide
- Liraglutide
- Tirzepatide
- Lixisenatide
- Semaglutide
The global GLP-1 agonists market is driven by key drugs such as dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. Among these, semaglutide dominates due to its efficacy in both type 2 diabetes and weight management. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is gaining traction for superior glycaemic control and weight loss. Dulaglutide and liraglutide maintain strong market presence due to their cardiovascular benefits. Continuous innovation in formulations, including extended-release injections and oral alternatives, is expected to drive market expansion, enhancing patient adherence and accessibility worldwide.
Market Breakup by Application
- Type 2 Diabetes Mellitus
- Obesity
GLP-1 agonists are primarily used for type 2 diabetes mellitus treatment, where they improve insulin secretion, reduce glucose levels, and lower cardiovascular risks. However, their increasing adoption for obesity management is transforming the market. Rising obesity rates and regulatory approvals for weight loss indications are accelerating growth. With growing awareness of metabolic health, GLP-1 agonists are expected to play a central role in obesity therapy, further expanding the market and creating new revenue streams for pharmaceutical companies.
Market Breakup by Route of Administration
- Parenteral
- Oral
Parenteral administration dominates the GLP-1 agonists market, with most drugs available as subcutaneous injections. Advances in once-weekly formulations have improved patient compliance, reducing injection frequency. However, the emergence of oral GLP-1 agonists, such as oral semaglutide, is revolutionising the market by offering a non-invasive alternative. The growing preference for oral drugs is expected to drive market growth, particularly in patients hesitant to use injectable therapies, expanding accessibility and adoption globally.
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Academic and Research Institutes
- Others
Hospitals account for the largest market share due to the increasing prevalence of diabetes-related hospitalisations and access to advanced treatments. Specialty clinics are witnessing significant growth as personalised diabetes and obesity management become more prevalent. Academic and research institutes play a crucial role in clinical trials and drug development. The others segment, including homecare settings, is expanding due to rising adoption of GLP-1 agonists for self-administration, driven by patient convenience and telemedicine advancements.
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Hospital pharmacies lead the distribution of GLP-1 agonists due to their strong integration with healthcare facilities and availability of prescription-based treatments. Retail pharmacies hold a substantial share, catering to outpatient prescriptions and chronic disease management. Online pharmacies are rapidly growing, driven by digital healthcare adoption, improved accessibility, and increasing patient preference for doorstep delivery, particularly in developed markets. The expansion of e-commerce in pharmaceuticals is expected to boost the online pharmacy segment significantly.
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
North America dominates the GLP-1 agonists market due to high diabetes prevalence, strong healthcare infrastructure, and early adoption of innovative therapies. Europe follows closely, benefiting from supportive government policies and rising obesity rates. Asia-Pacific is witnessing the fastest growth, driven by increasing healthcare investments, a growing diabetic population, and expanding pharmaceutical access. Latin America and the Middle East & Africa are emerging markets, with improving healthcare systems and rising awareness boosting GLP-1 agonist adoption. Expanding regulatory approvals and market penetration in developing regions will further fuel global market growth.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Competitive Landscape
The global GLP-1 agonists market is highly competitive, with major pharmaceutical companies focusing on innovation, strategic partnerships, and market expansion. Eli Lilly and Company, Sanofi, Novo Nordisk A/S, AstraZeneca plc, Pfizer Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, Amgen Inc., and GlaxoSmithKline plc are the key players driving market growth. Companies are actively engaging in mergers and acquisitions to strengthen their product portfolios and global presence. Research initiatives focus on next-generation GLP-1 agonists and combination therapies. Product introductions include oral formulations and extended-release injections. Strategic partnerships with biotech firms and healthcare providers are accelerating innovation and accessibility.
Key Questions Answered in the Report
What factors are driving the growth of the global GLP-1 agonists market?
How is the rising prevalence of diabetes and obesity influencing GLP-1 agonist adoption?
What are the advantages of GLP-1 agonists over traditional diabetes treatments?
How are oral GLP-1 agonists impacting the market compared to injectable formulations?
What role do research initiatives and clinical trials play in advancing GLP-1 therapies?
Which pharmaceutical companies are leading the global GLP-1 agonists market?
How are mergers, acquisitions, and partnerships shaping competition in the GLP-1 market?
What challenges does the GLP-1 agonists market face in terms of affordability and accessibility?
How is digital health technology improving patient adherence to GLP-1 agonist treatments?
What future opportunities exist for GLP-1 agonists beyond diabetes and obesity management?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global glucagon-like peptide-1 (GLP-1) Agonists market from 2018-2034.
The research report provides the latest information on the market drivers, challenges, and opportunities in the global glucagon-like peptide-1 (GLP-1) Agonists market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global glucagon-like peptide-1 (GLP-1) Agonists industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Overview
3.1 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Historical Value (2018-2024)
3.2 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Landscape*
5.1 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market: Product Landscape
5.2.1 Analysis By Drugs
5.2.2 Analysis By Application
5.2.3 Analysis By Route of Administration
6 Clinical Trials and Pipeline Analysis
6.1 Analysis by Trial Registration Year
6.2 Analysis by Trial Status
6.3 Analysis by Trial Phase
6.4 Analysis by Therapeutic Area
6.5 Analysis by Geography
6.6 Drug Pipeline Assessment
7 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Dynamics
7.1 Market Drivers and Constraints
7.2 SWOT Analysis
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats
7.3 PESTEL Analysis
7.3.1 Political
7.3.2 Economic
7.3.3 Social
7.3.4 Technological
7.3.5 Legal
7.3.6 Environment
7.4 Porter's Five Forces Model
7.4.1 Bargaining Power of Suppliers
7.4.2 Bargaining Power of Buyers
7.4.3 Threat of New Entrants
7.4.4 Threat of Substitutes
7.4.5 Degree of Rivalry
7.5 Key Demand Indicators
7.6 Key Price Indicators
7.7 Industry Events, Initiatives, and Trends
7.8 Value Chain Analysis
8 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation (218-2034)
8.1 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
8.1.1 Market Overview
8.1.2 Dulaglutide
8.1.3 Exenatide
8.1.4 Liraglutide
8.1.5 Tirzepatide
8.1.6 Lixisenatide
8.1.7 Semaglutide
8.2 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
8.2.1 Market Overview
8.2.2 Type 2 Diabetes Mellitus
8.2.3 Obesity
8.3 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
8.3.1 Market Overview
8.3.2 Parenteral
8.3.3 Oral
8.4 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
8.4.1 Market Overview
8.4.2 Hospitals
8.4.3 Specialty Clinics
8.4.4 Academic and Research Institutes
8.4.5 Others
8.5 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
8.5.1 Market Overview
8.5.2 Hospital Pharmacies
8.5.3 Retail Pharmacies
8.5.4 Online Pharmacies
8.6 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Region
8.6.1 Market Overview
8.6.2 North America
8.6.3 Europe
8.6.4 Asia Pacific
8.6.5 Latin America
8.6.6 Middle East and Africa
9 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
9.1 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
9.1.1 Market Overview
9.1.2 Dulaglutide
9.1.3 Exenatide
9.1.4 Liraglutide
9.1.5 Tirzepatide
9.1.6 Lixisenatide
9.1.7 Semaglutide
9.2 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
9.2.1 Market Overview
9.2.2 Type 2 Diabetes Mellitus
9.2.3 Obesity
9.3 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
9.3.1 Market Overview
9.3.2 Parenteral
9.3.3 Oral
9.4 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
9.4.1 Market Overview
9.4.2 Hospitals
9.4.3 Specialty Clinics
9.4.4 Academic and Research Institutes
9.4.5 Others
9.5 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
9.5.1 Market Overview
9.5.2 Hospital Pharmacies
9.5.3 Retail Pharmacies
9.5.4 Online Pharmacies
9.6 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
9.6.1 United States of America
9.6.1.1 United States of America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
9.6.2 Canada
9.6.2.1 Canada Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
10 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
10.1 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
10.1.1 Market Overview
10.1.2 Dulaglutide
10.1.3 Exenatide
10.1.4 Liraglutide
10.1.5 Tirzepatide
10.1.6 Lixisenatide
10.1.7 Semaglutide
10.2 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
10.2.1 Market Overview
10.2.2 Type 2 Diabetes Mellitus
10.2.3 Obesity
10.3 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
10.3.1 Market Overview
10.3.2 Parenteral
10.3.3 Oral
10.4 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
10.4.1 Market Overview
10.4.2 Hospitals
10.4.3 Specialty Clinics
10.4.4 Academic and Research Institutes
10.4.5 Others
10.5 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
10.5.1 Market Overview
10.5.2 Hospital Pharmacies
10.5.3 Retail Pharmacies
10.5.4 Online Pharmacies
10.6 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
10.6.1 United Kingdom
10.6.1.1 United Kingdom Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
10.6.2 Germany
10.6.2.1 Germany Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
10.6.3 France
10.6.3.1 France Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
10.6.4 Italy
10.6.4.1 Italy Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
10.6.5 Others
11 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
11.1 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
11.1.1 Market Overview
11.1.2 Dulaglutide
11.1.3 Exenatide
11.1.4 Liraglutide
11.1.5 Tirzepatide
11.1.6 Lixisenatide
11.1.7 Semaglutide
11.2 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
11.2.1 Market Overview
11.2.2 Type 2 Diabetes Mellitus
11.2.3 Obesity
11.3 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
11.3.1 Market Overview
11.3.2 Parenteral
11.3.3 Oral
11.4 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Specialty Clinics
11.4.4 Academic and Research Institutes
11.4.5 Others
11.5 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacies
11.5.3 Retail Pharmacies
11.5.4 Online Pharmacies
11.6 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
11.6.1 China
11.6.1.1 China Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
11.6.2 Japan
11.6.2.1 Japan Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
11.6.3 India
11.6.3.1 India Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
11.6.4 ASEAN
11.6.4.1 ASEAN Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
11.6.5 Australia
11.6.5.1 Australia Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
11.6.6 Others
12 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
12.1 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
12.1.1 Market Overview
12.1.2 Dulaglutide
12.1.3 Exenatide
12.1.4 Liraglutide
12.1.5 Tirzepatide
12.1.6 Lixisenatide
12.1.7 Semaglutide
12.2 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
12.2.1 Market Overview
12.2.2 Type 2 Diabetes Mellitus
12.2.3 Obesity
12.3 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
12.3.1 Market Overview
12.3.2 Parenteral
12.3.3 Oral
12.4 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
12.4.1 Market Overview
12.4.2 Hospitals
12.4.3 Specialty Clinics
12.4.4 Academic and Research Institutes
12.4.5 Others
12.5 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
12.5.1 Market Overview
12.5.2 Hospital Pharmacies
12.5.3 Retail Pharmacies
12.5.4 Online Pharmacies
12.6 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
12.6.1 Brazil
12.6.1.1 Brazil Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
12.6.2 Argentina
12.6.2.1 Argentina Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
12.6.3 Mexico
12.6.3.1 Mexico Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
12.6.4 Others
13 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
13.1 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
13.1.1 Market Overview
13.1.2 Dulaglutide
13.1.3 Exenatide
13.1.4 Liraglutide
13.1.5 Tirzepatide
13.1.6 Lixisenatide
13.1.7 Semaglutide
13.2 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
13.2.1 Market Overview
13.2.2 Type 2 Diabetes Mellitus
13.2.3 Obesity
13.3 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
13.3.1 Market Overview
13.3.2 Parenteral
13.3.3 Oral
13.4 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
13.4.1 Market Overview
13.4.2 Hospitals
13.4.3 Specialty Clinics
13.4.4 Academic and Research Institutes
13.4.5 Others
13.5 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
13.5.1 Market Overview
13.5.2 Hospital Pharmacies
13.5.3 Retail Pharmacies
13.5.4 Online Pharmacies
13.6 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
13.6.1 Saudi Arabia
13.6.1.1 Saudi Arabia Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
13.6.2 United Arab Emirates
13.6.2.1 United Arab Emirates Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
13.6.3 Nigeria
13.6.3.1 Nigeria Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
13.6.4 South Africa
13.6.4.1 South Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
13.6.5 Others
14 Regulatory Framework
14.1 Regulatory Overview
14.2 US FDA
14.3 EU EMA
14.4 INDIA CDSCO
14.5 JAPAN PMDA
14.6 Others
15 Patent Analysis
15.1 Analysis By Drug Type of Patent
15.2 Analysis by Publication Year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
16 Grants Analysis
16.1 Analysis by Year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Drug Class of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Strategic Initiatives
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Initiatives
18.3 Analysis by Joint Ventures
18.4 Analysis by Leading Players
18.5 Analysis by Geography
19 Supplier Landscape
19.1 Market Share Analysis, By Region (Top 5 Companies)
19.1.1 Market Share Analysis: Global
19.1.2 Market Share Analysis: North America
19.1.3 Market Share Analysis: Europe
19.1.4 Market Share Analysis: Asia Pacific
19.1.5 Market Share Analysis: Others
19.2 Eli Lilly and Company
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Company News and Development
19.2.5 Certifications
19.3 Sanofi
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Company News and Development
19.3.5 Certifications
19.4 Novo Nordisk A/S
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Company News and Development
19.4.5 Certifications
19.5 AstraZeneca plc
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Company News and Development
19.5.5 Certifications
19.6 Pfizer Inc.
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Company News and Development
19.6.5 Certifications
19.7 Boehringer Ingelheim
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Company News and Development
19.7.5 Certifications
19.8 F. Hoffmann-La Roche
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Company News and Development
19.8.5 Certifications
19.9 Amgen Inc.
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Company News and Development
19.9.5 Certifications
19.10 GlaxoSmithKline plc
19.10.1 Financial Analysis
19.10.2 Product Portfolio
19.10.3 Demographic Reach and Achievements
19.10.4 Company News and Development
19.10.5 Certifications
20 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market - Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security